{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:32Z","timestamp":1789746212858,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,12]]},"DOI":"10.7759\/cureus.41781","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:35:04Z","timestamp":1689179704000},"source":"Crossref","is-referenced-by-count":5,"title":["Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Danielle","family":"Brazel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungshin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Warnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes SA","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019, 145:1527-57. 10.1007\/s00432-019-02927-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the Phase IIIB\/IV Checkmate 511 trial","volume":"37","author":"Lebb\u00e9 C","year":"2019","unstructured":"Lebb\u00e9 C, Meyer N, Mortier L, et al.. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the Phase IIIB\/IV Checkmate 511 trial. J Clin Oncol. 2019, 37:867-75. 10.1200\/JCO.18.01998","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9004","article-title":"Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study","volume":"33","author":"Hodi FS","year":"2015","unstructured":"Hodi FS, Postow MA, Chesney JA, et al.. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. J Clin Oncol. 2015, 33:9004. 10.1200\/jco.2015.33.15_suppl.9004","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax AJ","year":"2017","unstructured":"Lomax AJ, McGuire HM, McNeil C, et al.. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017, 20:1277-85. 10.1111\/1756-185X.13076","journal-title":"Int J Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber JS","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013, 119:1675-82. 10.1002\/cncr.27969","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino M","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015, 373:288-90. 10.1056\/NEJMc1505197","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy LB","year":"2020","unstructured":"Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020, 70:86-104. 10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0384-0","article-title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","volume":"6","author":"Hantel A","year":"2018","unstructured":"Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018, 6:73. 10.1186\/s40425-018-0384-0","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid J","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015, 4:560-75. 10.3978\/j.issn.2218-6751.2015.06.06","journal-title":"Transl Lung Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4 therapy","volume":"42","author":"Gupta A","year":"2015","unstructured":"Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015, 42:406-17. 10.1111\/apt.13281","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman DL","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018, 38:976-87. 10.1111\/liv.13746","journal-title":"Liver Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar FB","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al.. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016, 90:638-47. 10.1016\/j.kint.2016.04.008","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy N","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al.. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019, 6:48. 10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2019.02.004","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","author":"Upadhrasta S","year":"2019","unstructured":"Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019, 5:6-14. 10.1016\/j.cdtm.2019.02.004","journal-title":"Chronic Dis Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling L","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, et al.. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016, 4:50. 10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier M","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017, 136:2085-7. 10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis","volume":"16","author":"Grover S","year":"2020","unstructured":"Grover S, Ruan AB, Srivoleti P, et al.. Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract. 2020, 16:e933-42. 10.1200\/JOP.19.00672","journal-title":"JCO Oncol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/156028-multiorgan-failure-from-nivolumab-and-ipilimumab-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:46Z","timestamp":1707509026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/156028-multiorgan-failure-from-nivolumab-and-ipilimumab-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.41781","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}